CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Tom P. Freeman

OPENALEX: A5047194230↗OPENALEX: A5126944919↗OPENALEX: A5135170653↗OPENALEX: A5136267649↗ORCID: 0000-0002-5667-507X↗

Affiliations

Organizations

Aarhus Universityauthorship · DK Abilities In Motionauthorship · US Bath Spa Universityauthorship · GB Centre for Addiction and Mental Healthauthorship · CA Chinese University of Hong Kongauthorship · HK Edinburgh Collegeauthorship · GB Health Data Research UKauthorship · GB HKU-Pasteur Research Poleauthorship · HK Institute of Mental Healthauthorship · GB King's College Londonauthorship · GB Maastricht University Medical Centreauthorship · NL Mental Health Research UKauthorship · GB MRC Cancer Unitauthorship · GB National Drug Addiction Centerauthorship · BG The University of Sydneyauthorship · AU University College Londonauthorship · GB University of Bathauthorship · GB University of Edinburghauthorship · GB University of Hong Kongauthorship · HK

Public evidence

61 connected articles

Medical cannabis in the UK: prescriptions, sources, products and high-risk use2026 · medRxiv Examining the independent roles of cannabis use and tobacco use in depression risk: a multivariable Mendelian randomisation study2024 · medRxiv Associations of cannabis use, tobacco use and incident anxiety, mood, and psychotic disorders: a systematic review and meta-analysis2023 · medRxiv The use of cannabis for medical reasons in the UK: Prescriptions, sources, products, and high-risk use.2026 · PubMed Central Open Access The association between cannabis use and brain reward anticipation: a 12-month longitudinal study of adults and adolescents who use cannabis and age-matched controls2026 · PubMed Central Open Access Changes in cannabis potency and cannabis-related psychiatric harms: a 23-year ecological study in Denmark.2026 · Europe PMC Persistent increased severity of cannabis use disorder symptoms in adolescents compared to adults: a one-year longitudinal study.2025 · Europe PMC Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.2025 · Europe PMC Association of childhood mental health and cognition with longitudinal patterns of cannabis problems in adolescence.2025 · Europe PMC The impact of childhood trauma and cannabis use on paranoia: a structural equation model approach.2025 · Europe PMC

Registered research

Connected studies

A Phase IIa/b, Randomised, Double-blind, Placebo-controlled, Single-site, Parallel Group Clinical Trial to Examine Cannabidiol (CBD) as a Pharmacological Treatment for Cannabis Dependence.nct02044809 Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol?nct04851392 Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Studynct04605393 Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Usenct06218056 Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Rationct05170217 Testing the Efficacy of the Cannabis Clinic for Patients With Psychosis (CCP) Intervention for Cannabis Use Reduction/Cessation in Patients With First Episode Psychosisnct07245212

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Applying machine learning to international drug monitoring: classifying cannabis resin collected in Europe using cannabinoid concentrations.

2025 · Europe PMC

Longitudinal study of risk factors predicting cannabis use disorder in UK young adults and adolescents.2025 · Europe PMC

Are reasons for first using cannabis associated with subsequent cannabis consumption (standard THC units) and psychopathology?2025 · Europe PMC

Methylomic signature of current cannabis use in two first-episode psychosis cohorts.2025 · Europe PMC

Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.2025 · Europe PMC

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMC

A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.2024 · Europe PMC

Acute effects of different types of cannabis on young adult and adolescent resting-state brain networks.2024 · Europe PMC

A proof-of-concept analysis of data from the first NHS clinic for young adults with comorbid cannabis use and psychotic disorders.2024 · Europe PMC

The acute effects of cannabis, with and without cannabidiol, on attentional bias to cannabis related cues: a randomised, double-blind, placebo-controlled, cross-over study.2024 · Europe PMC

Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.2024 · Europe PMC

Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder.2023 · Europe PMC

Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder.2023 · PubMed Central Open Access

Different Tokes for Different Folks: Use of Cannabis Products Among a Longitudinal Cohort of People with Heroin Dependence.2023 · PubMed Central Open Access

Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMC

Anhedonia, Apathy, Pleasure, and Effort-Based Decision-Making in Adult and Adolescent Cannabis Users and Controls.2023 · PubMed Central Open Access

The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.2023 · PubMed Central Open Access

The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMC

Legal sourcing of ten cannabis products in the Canadian cannabis market, 2019-2021: a repeat cross-sectional study.2023 · PubMed Central Open Access

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.2023 · Europe PMC

Tom P. Freeman - Medical Cannabis Research Engine